Figure 1
From: Serum fibronectin distinguishes the early stages of hepatocellular carcinoma
Overall scheme of the study. Reproducibly detected peptides were selected from pooled serum samples of hepatocellular carcinoma patients. In the training set of 30 liver cirrhosis, 30 hepatocellular carcinoma, and 30 recovered patients, significantly differentiated proteins were verified. The single targets with AUROC values ≥ 0.800 were tested in 90 independent samples, composed of liver cirrhosis, hepatocellular carcinoma, and recovered patients. The final target, FN1, was verified by antibody-based assays, such as western blot. FN1 was combined with AFP into a 2-marker panel which was validated in 60 independent samples by ELISA.
